Source:http://linkedlifedata.com/resource/pubmed/id/19093883
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2009-1-15
|
pubmed:abstractText |
The reversal of multidrug resistance by 22 molecules [8-aryl-8-hydroxy-5-R'-8H-[1,4]thiazino[3,4-c][1,2,4]oxadiazol-3-ones (1a-i) and 8-aryl-8-alkoxy-5-methyl-8H-[1,4]thiazino[3,4-c][1,2,4]oxadiazol-3-ones (2a-m)] related to myocardial-calcium-channel-modulator diltiazem was studied in multidrug resistant A2780/DX3 and their sensitive counterpart A2780 cells. MTT, cytofluorimetry assays, and fluorescence microscopy analyses were used to define activity and accumulation of doxorubicin with or without the diltiazem-like modulators. Of the 22 molecules, 1a, 2f, 2g, and 2m were able to overcome the established criteria for the selection in A2780/DX3 cells (IC(50) reduction > or = 25%), but only 2f, 2g, and 2m caused a significant increase of intracellular accumulation of doxorubicin. In conclusion, experiments lead to the identification of three diltiazem-like molecules able to increase the intracellular accumulation of doxorubicin by inhibiting the MDR1 function, thus potentiating its antiproliferative activity in multidrug resistant A2780/DX3 cells.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1520-4804
|
pubmed:author |
pubmed-author:AielloCinziaC,
pubmed-author:CastagnolaPatrizioP,
pubmed-author:CianfrigliaMaurizioM,
pubmed-author:CordazzoCinziaC,
pubmed-author:CosimelliBarbaraB,
pubmed-author:PetrilloGiovanniG,
pubmed-author:SeveriEldaE,
pubmed-author:SpinelliDomenicoD,
pubmed-author:VialeMaurizioM,
pubmed-author:de ToteroDanielaD
|
pubmed:issnType |
Electronic
|
pubmed:day |
22
|
pubmed:volume |
52
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
259-66
|
pubmed:meshHeading |
pubmed-meshheading:19093883-Antineoplastic Agents,
pubmed-meshheading:19093883-Cell Line,
pubmed-meshheading:19093883-Cell Proliferation,
pubmed-meshheading:19093883-Diltiazem,
pubmed-meshheading:19093883-Doxorubicin,
pubmed-meshheading:19093883-Drug Resistance, Multiple,
pubmed-meshheading:19093883-Flow Cytometry,
pubmed-meshheading:19093883-Fluorescent Antibody Technique,
pubmed-meshheading:19093883-Humans,
pubmed-meshheading:19093883-Microscopy, Fluorescence,
pubmed-meshheading:19093883-P-Glycoprotein
|
pubmed:year |
2009
|
pubmed:articleTitle |
Inhibition of MDR1 activity in vitro by a novel class of diltiazem analogues: toward new candidates.
|
pubmed:affiliation |
Istituto Nazionale per la Ricerca sul Cancro, S.C. Terapia Immunologica, L.go R. Benzi 10, 16132 Genova, Italy.
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, Non-U.S. Gov't
|